StockMarketWire.com - Circassia Pharmaceuticals has announced the positive outcome of the European Decentralised Procedure (DCP) for the company's fluticasone propionate pressurised metered dose inhaler (pMDI) generic equivalent of GlaxoSmithKline's FLIXOTIDE pMDI for the prophylactic treatment of asthma.

Under the DCP, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) acted as the reference member state.

The MHRA agrees that the product can be approved and issue of the national licence will now commence. Based on initial national Marketing Authorisations following the DCP, the product will be submitted under the Mutual Recognition Procedure for approval in other EU Member States.




Story provided by StockMarketWire.com